Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest MVA85A Stories

Tuberculosis Vaccine Shows Promising Results
2013-10-03 04:39:56

redOrbit Staff & Wire Reports - Your Universe Online Canadian researchers have developed a new tuberculosis vaccine that could boost or perhaps replace the only existing way to immunize against the infection. The researchers say the new vaccine is an important breakthrough because the current tuberculosis vaccine is not effective enough to curb the TB epidemic in some parts of the world. "We are the first to have developed such a vaccine for tuberculosis," said Dr. Fiona Smaill,...

Tuberculosis Vaccine Fails Infant Trial
2013-02-04 14:42:30

[ Watch the Video: Discussing New Tuberculosis Vaccine Trials ] Lee Rannals for redOrbit.com - Your Universe Online A new vaccine considered to be the most advanced for tuberculosis (TB) among more than a dozen now in trials has failed its study. Researchers said they were disappointed by the results of the study, which showed that the vaccine offered little to no protection at all from TB. Nearly 3,000 babies in South Africa took part in the study, all of whom had already been...

2012-03-21 05:45:41

(Ivanhoe Newswire) — New, more effective vaccines will be decisive in the fight against TB. More than 10 million children have been orphaned by the disease, which is rapidly becoming resistant to available treatment options. Top scientific experts, all over the world, are working together to develop a vaccine that will eliminate TB on all fronts and levels. To address the many challenges posed by TB, ideal vaccine regimens must protect babies at birth from childhood TB, and prevent...

2008-07-23 12:01:24

The University of Oxford and Emergent BioSolutions have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium, to further develop MVA85A, a clinically advanced vaccine candidate for the prevention of tuberculosis. The University of Oxford, through its technology transfer office, Isis Innovation, has exclusively licensed the MVA85A tuberculosis (TB) vaccine candidate and related technology to the consortium. The consortium will work with the Aeras Global TB Vaccine Foundation...

2008-07-23 00:00:46

The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) announced today that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd. (the "Consortium"), to further develop MVA85A, the world's most clinically advanced vaccine candidate for the prevention of tuberculosis. The University of Oxford, through its technology transfer office, Isis Innovation Limited, has exclusively licensed the MVA85A tuberculosis vaccine candidate and related technology to the...

2005-08-01 13:31:23

By Patricia Reaney LONDON (Reuters) - Tuberculosis vaccines being tested in developed countries will not protect people living in parts of the developing world where they are most needed because they trigger a different body response, researchers said on Monday. Scientists at University College London (UCL), who looked at variations in immune system responses around the globe, found that in countries near the equator the tuberculosis bacteria turn the body's normal protective response into...